A phase 1 experimental medicine study of anti-CD3 monoclonal antibody in rheumatoid arthritis
At the dosing regimen used, otelixizumab was associated with an unexpected and significant first-dose reaction in participants with RA.
Authors
- G Hale (ORCID: https://orcid.org/0000-0001-9473-423X)
- CA Lawson (ORCID: https://orcid.org/0009-0008-3226-8948)
- Bridget Griffiths (ORCID: https://orcid.org/0000-0001-5568-572X)
- John D. Isaacs (ORCID: https://orcid.org/0000-0002-6103-7056)
- Herman Waldmann (ORCID: https://orcid.org/0000-0001-7519-6720)
- Rachel A. Harry
Institutions
- St James's University Hospital (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- University of Oxford (GB)
- Clinical Research Institute (US)
- NIHR Leeds Musculoskeletal Biomedical Research Unit (GB)
- NIHR Newcastle Biomedical Research Centre (GB)
- University of Newcastle Australia (AU)
- Newcastle University (GB)
Publication Details
- Journal
- Immunotherapy Advances
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1093/immadv/ltaf034
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute for Health and Care Research
- Newcastle University
- Takeda Oncology
- NIHR Newcastle Biomedical Research Centre